Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February28, 2019, Eagle Pharmaceuticals,Inc., or the Company, issued a press release announcing its financial results for the fiscal fourth quarter and fiscal year ended December31, 2018. A copy of the Company’s press release is furnished as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.
The information in this Current Report on Form8-K, including the information contained in the press release furnished as Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
EAGLE PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a19-5576_1ex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals,…
To view the full exhibit click here
About Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX)
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.
